(Reuters) — AstraZeneca said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash.
The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share.
FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021.
Visited 3 times, 1 visit(s) today
